Company news
Avita Medical, Inc. news in 2022
Avita Medical, Inc.'s news releases, calls and decks from 2022, newest first.
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
December 18, 2022
AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
December 11, 2022
AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
December 11, 2022
AVITA Medical Reports Third Quarter 2022 Financial Results
November 9, 2022
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
November 8, 2022
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
November 2, 2022
AVITA Medical to Announce Third Quarter 2022 Financial Results
October 19, 2022
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
September 27, 2022
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
September 11, 2022
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns
August 31, 2022
AVITA Medical Reports Second Quarter 2022 Financial Results
August 10, 2022
AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System
August 10, 2022
AVITA Medical to Announce Second Quarter 2022 Financial Results
July 24, 2022
AVITA Medical Reports First Quarter 2022 Financial Results
May 11, 2022
AVITA Medical to Announce First Quarter 2022 Financial Results
April 27, 2022
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors
April 20, 2022
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
March 20, 2022
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
March 1, 2022
AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
February 27, 2022
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
February 22, 2022
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
February 16, 2022
AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
January 9, 2022
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
January 5, 2022
Calls in 2022
Decks in 2022
- Shareholder Meeting (December 2022)
Shareholder meeting · 48 slides · Dec 12, 2022
- Investor Presentation (September 2022)
Investor deck · 22 slides · Sep 20, 2022
- Investor Presentation (August 2022)
Investor deck · 39 slides · Aug 30, 2022
- Q1 2022 Earnings Presentation
Earnings · 41 slides · May 17, 2022
- Investor Presentation (May 2022)
Investor deck · 41 slides · May 12, 2022
- Cowen Conference 2022
Conference · 40 slides · Mar 8, 2022
- JP Morgan Healthcare Conference 2022
Conference · 40 slides · Jan 11, 2022